AU2003220096A1 - Methods for alzheimer's disease treatment and cognitive enhancement - Google Patents

Methods for alzheimer's disease treatment and cognitive enhancement

Info

Publication number
AU2003220096A1
AU2003220096A1 AU2003220096A AU2003220096A AU2003220096A1 AU 2003220096 A1 AU2003220096 A1 AU 2003220096A1 AU 2003220096 A AU2003220096 A AU 2003220096A AU 2003220096 A AU2003220096 A AU 2003220096A AU 2003220096 A1 AU2003220096 A1 AU 2003220096A1
Authority
AU
Australia
Prior art keywords
alzheimer
methods
disease treatment
cognitive enhancement
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003220096A
Other languages
English (en)
Other versions
AU2003220096A8 (en
Inventor
Daniel L. Alkon
Rene Etcheberrigaray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Publication of AU2003220096A8 publication Critical patent/AU2003220096A8/xx
Publication of AU2003220096A1 publication Critical patent/AU2003220096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003220096A 2002-03-07 2003-03-07 Methods for alzheimer's disease treatment and cognitive enhancement Abandoned AU2003220096A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36208002P 2002-03-07 2002-03-07
US60/362,080 2002-03-07
US10/167,491 US6825229B2 (en) 2002-03-07 2002-06-13 Methods for Alzheimer's Disease treatment and cognitive enhancement
US10/167,491 2002-06-13
PCT/US2003/007101 WO2003075850A2 (en) 2002-03-07 2003-03-07 Methods for alzheimer's disease treatment and cognitive enhancement

Publications (2)

Publication Number Publication Date
AU2003220096A8 AU2003220096A8 (en) 2003-09-22
AU2003220096A1 true AU2003220096A1 (en) 2003-09-22

Family

ID=27807411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003220096A Abandoned AU2003220096A1 (en) 2002-03-07 2003-03-07 Methods for alzheimer's disease treatment and cognitive enhancement

Country Status (7)

Country Link
US (4) US6825229B2 (enExample)
EP (2) EP1490050B1 (enExample)
JP (1) JP2005527512A (enExample)
AU (1) AU2003220096A1 (enExample)
CA (1) CA2477973A1 (enExample)
ES (1) ES2639578T3 (enExample)
WO (1) WO2003075850A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20070037871A1 (en) * 2002-07-02 2007-02-15 Blanchette Rockefeller Neurosciences Instiute Pkc activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds
KR20050094761A (ko) * 2002-07-02 2005-09-28 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 브리오스타틴형 화합물을 사용한 ｓＡＰＰα 분비의 증진및 인지 개선을 위한 수단으로서의 ＰＫＣ 활성화
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
WO2006094673A2 (en) * 2005-03-08 2006-09-14 Ludwig-Maximilians-Universität München Synergistic mixtures of c6- to c12-alkanedi0ls and tropolone (derivatives)
KR20130122630A (ko) 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
EP2762136A1 (en) * 2006-07-28 2014-08-06 Blanchette Rockefeller Neurosciences, Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
US20170319541A9 (en) * 2006-07-28 2017-11-09 Blanchette Rockefeller Neuroscience Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
PT2048145E (pt) * 2006-08-04 2011-01-14 Toyama Chemical Co Ltd Agente incrementando a actividade da proteína quinase c, contendo um derivado de um éter alquílico, ou um seu sal
EP3332797A3 (en) * 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
JP5290209B2 (ja) * 2007-03-09 2013-09-18 クゥアルコム・インコーポレイテッド 直交変調回転トレーニング・シーケンス
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
WO2009099563A2 (en) * 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
WO2009129361A2 (en) 2008-04-16 2009-10-22 University Of Utah Research Foundation Macrocyclic compounds and methods of making and using thereof
EP2669386A1 (en) 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
ES2538208T3 (es) * 2010-02-22 2015-06-18 Blanchette Rockefeller Neurosciences Institute Alteraciones específicas de la enfermedad de Alzheimer de los niveles de proteína quinasa C épsilon (PKC-épsilon)
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
EP2605773A1 (en) * 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
CN105228614A (zh) 2012-11-28 2016-01-06 阿菲欧斯公司 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法
US20160025704A1 (en) * 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
EP3294290A1 (en) * 2015-05-11 2018-03-21 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US20180256537A1 (en) 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
WO2017062924A1 (en) 2015-10-08 2017-04-13 Alkon Daniel L Dosing regimens of pkc activators
US20190125721A1 (en) * 2016-05-04 2019-05-02 Neurotrope Bioscience, Inc. Methods and compositions for treatment of rett syndrome
US20190350898A1 (en) * 2018-05-18 2019-11-21 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
EP4262777A4 (en) * 2020-12-16 2025-01-01 Synaptogenix, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PKC ACTIVATORS

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
FI840260L (fi) 1983-01-27 1984-07-28 Ciba Geigy Ag Pyrrolidinonderivat och foerfarande foer deras framstaellning.
US4611066A (en) 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5955501A (en) 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US6043270A (en) * 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4833257A (en) 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
DE68910704T2 (de) 1988-01-13 1994-04-07 Univ Arizona Immunmodulierende Bryostatine.
US4833139A (en) 1988-01-25 1989-05-23 Hoechst-Roussel Pharmaceuticals, Inc. Enhancing cholinergic activity with 5-substituted 1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinones and related compounds
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4994472A (en) 1989-08-02 1991-02-19 Hoechst-Roussel Pharmaceuticals Incorporated 1-(pyridinylamino)-2-pyrrolidinones as pain relievers
AU6886791A (en) 1989-11-13 1991-06-13 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
EP1046421B8 (en) 1990-12-06 2006-01-11 Affymetrix, Inc. (a Delaware Corporation) Methods and reagents for very large scale immobilized polymer synthesis
US5072004A (en) 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5196447A (en) 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
ATE262374T1 (de) 1991-11-22 2004-04-15 Affymetrix Inc Kombinatorische strategien für polymersynthese
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
CA2143848C (en) 1992-10-01 2007-09-11 W. Clark Still Complex combinatorial chemical libraries encoded with tags
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US5580748A (en) 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease
US5393897A (en) 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
WO1995009160A1 (en) 1993-09-30 1995-04-06 Shionogi & Co., Ltd. Benzolactam derivative
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5430053A (en) * 1994-04-19 1995-07-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of dictyostatin 1
US5625232A (en) 1994-07-15 1997-04-29 Texas Instruments Incorporated Reliability of metal leads in high speed LSI semiconductors using dummy vias
FI971995A7 (fi) 1994-11-10 1997-05-09 Pfizer Makrosykliset laktoniyhdisteet ja niiden tuotantomenetelmä
GB9509572D0 (en) * 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
CA2253463A1 (en) 1996-05-10 1997-11-20 Georgetown University 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and their use as protein kinase c (=pkc) modulators
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9701675D0 (en) 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
WO1999012901A1 (en) 1997-09-08 1999-03-18 Georgetown University Substituted 2-pyrrolidinone activators of pkc
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
DE19943198A1 (de) 1999-09-09 2001-03-15 Meyer Lucas Gmbh & Co Therapeutikum zur Behebung zentralnervöser Funktionsstörungen
JP2003515601A (ja) 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
JP2001240581A (ja) * 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
AU2001243635A1 (en) 2000-03-14 2001-09-24 Brown University Research Foundation Methods and compositions for regulating memory consolidation
WO2001083449A2 (en) * 2000-04-28 2001-11-08 Georgetown University Rigid pyrrolidone modulators of pkc
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
US20030050302A1 (en) * 2000-08-31 2003-03-13 Neurologic, Inc. Treatment of conditions associated with amyloid processing using PKC activators
EP1195159B1 (en) 2000-10-09 2006-05-31 Rath, Matthias, Dr. med. Therapeutic combination of ascorbate with lysine and arginine for prevention and treatment of cancer
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
AUPR215700A0 (en) 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
JP2004527500A (ja) 2001-03-01 2004-09-09 ファイザー・プロダクツ・インク 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンｅとｇａｂａａ逆アゴニストの併用
WO2002083877A1 (en) 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
EP1385938A1 (en) 2001-04-23 2004-02-04 Nsgene A/S Method and culture medium for producing neural cells expressing tyrosine hydroxylase
DE60229371D1 (de) 2001-05-02 2008-11-27 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
CA2401452A1 (en) 2001-09-04 2003-03-04 Uri Saragovi Combination of antioxidant substances for the treatment of alzheimer's disease
JP4568464B2 (ja) 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US6821979B2 (en) 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
KR20050094761A (ko) 2002-07-02 2005-09-28 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 브리오스타틴형 화합물을 사용한 ｓＡＰＰα 분비의 증진및 인지 개선을 위한 수단으로서의 ＰＫＣ 활성화
US20040229292A1 (en) 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
US7803400B2 (en) 2002-12-03 2010-09-28 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
AU2004277400B2 (en) 2003-09-30 2009-01-22 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
KR20130122630A (ko) 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
EP2762136A1 (en) 2006-07-28 2014-08-06 Blanchette Rockefeller Neurosciences, Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
JP5987867B2 (ja) 2014-07-10 2016-09-07 コニカミノルタ株式会社 シート搬送装置および画像形成システム

Also Published As

Publication number Publication date
AU2003220096A8 (en) 2003-09-22
WO2003075850A3 (en) 2004-01-08
EP2172246A2 (en) 2010-04-07
US20050037984A1 (en) 2005-02-17
EP2172246A3 (en) 2010-05-05
WO2003075850A2 (en) 2003-09-18
CA2477973A1 (en) 2003-09-18
EP1490050B1 (en) 2019-01-30
US20130281522A1 (en) 2013-10-24
ES2639578T3 (es) 2017-10-27
US20160051509A1 (en) 2016-02-25
WO2003075850A9 (en) 2004-02-19
JP2005527512A (ja) 2005-09-15
US20030171356A1 (en) 2003-09-11
US9539235B2 (en) 2017-01-10
US9446020B2 (en) 2016-09-20
EP1490050A2 (en) 2004-12-29
US6825229B2 (en) 2004-11-30
EP2172246B1 (en) 2017-08-30
EP1490050A4 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2002319615A1 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003284968A1 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
AU2003273213A1 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU2002302238A1 (en) A method of treatment of alzheimer's disease and device therefor
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
PL377110A1 (pl) Zapobieganie i leczenie choroby Alzheimera
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2003230848A1 (en) Methods and compositions for treating alzheimer's disease
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AUPS246502A0 (en) Method for the treatment of multiple sclerosis and alzheimer's disease
AUPS246702A0 (en) Method for the treatment of multiple sclerosis and alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase